Trial Profile
A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus Clopidogrel in Subjects With Acute Coronary Syndromes Who Are Receiving Clopidogrel.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Clopidogrel
- Indications Acute coronary syndromes; Embolism and thrombosis
- Focus Pharmacodynamics
- Acronyms SWAP
- Sponsors Eli Lilly and Company
- 13 Sep 2010 Results have been published in the Journal of the American College of Cardiology, according to an Eli Lilly media release.
- 16 Mar 2010 Patient numbers amended from 142 to 139 as reported by ClinicalTrials.gov.
- 21 Jul 2009 Actual end date (1 Dec 2008) added as reported by ClinicalTrials.gov.